Friday, July 31, 2026

Seattle Seahawks Begin Sale Process After Super Bowl Victory: What’s Next for the NFL Team?

The Seattle Seahawks, fresh off their Super Bowl LVIII win, are set to change ownership, fulfilling Paul Allen's philanthropic vision.

North Korea Condemns U.S.-Led Military Drills, Warns of Escalating Regional Tensions

South Korea, U.S., and Japan conducted joint military exercises, prompting North Korea to demand a halt and criticize rising tensions.

From Pyongyang with Trash: North Korea’s Balloon Provocation Continues!

North Korea has initiated yet another balloon campaign to send propaganda and waste to South Korea just three days after the last incident.

Tag: autoimmune diseases

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Celltrion Files for European Approval of Cosentyx Biosimilar, Targets $6.7 Billion Market

Celltrion has filed for European approval of its CT-P55 biosimilar for autoimmune diseases, aiming for early market entry and expansion.

Cevidoplenib: The Game-Changing Autoimmune Drug Set for Global Launch in 2026

Oscotec's Cevidoplenib, an autoimmune drug, is set for global development with Agios, promising significant growth and revenue potential.

How Penetrium’s Innovative Approach Could Change Cancer Treatment Forever

Penetrium Bioscience will unveil a new therapeutic mechanism for treating cancer and other diseases on April 16 in Seoul.

Imeroprubart vs. Batoclimab: Which Treatment Will Revolutionize Graves’ Disease Management?

HanAll Biopharma's Imeroprubart targets Graves' disease, showing promise with IgG suppression and user-friendly auto-injector delivery.

Celltrion’s Remsima SC: The Leading Autoimmune Drug with 68% Market Share in Europe

Celltrion's treatments for autoimmune diseases and cancer maintain strong market positions in Europe, bolstered by stable prescriptions and new products.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.